
    
      This study has a dose escalation (Ib) and dose expansion phase (II). The ALT-803 treatment in
      the Phase Ib portion of the study will escalate until a recommended dose level is decided.
      This dose level will be used in the phase II portion of the study. The Phase II potion of the
      study will include two groups: Nivolumab naive and Nivolumab progressing. Patients will be
      enrolled to one of the arms based on their previous treatment with Nivolumab.
    
  